Press Releases

Please Select Year

Advanced Accelerator Applications to Build Targeted RadioLigand Therapy Production Facility in Indianapolis

Jun 30, 2020

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours

Apr 7, 2020

Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera® as First-Line Treatment in Patients with Advanced GEP-NETs

Mar 25, 2020

Advanced Accelerator Applications Announces State of Israel Ministry of Health Approval for Lutathera®, in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Jul 29, 2019

Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu) Oxodotreotide (Lutathera®)

Jun 5, 2019

Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Feb 7, 2019

Novartis successfully completes acquisition of Endocyte

Dec 21, 2018

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications

Dec 3, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Oct 19, 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer – Second Theragnostic Program for Oncology Enters the Clinic

Jun 22, 2018

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

Jun 7, 2018

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

Feb 12, 2018

Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer

Feb 1, 2018

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Jan 26, 2018

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

Jan 22, 2018

Media Contacts

Rachel Levine
Global Head of Communications and Patient Advocacy
rachel.levine@adacap.com
+1-917-375-2935

Veronique Mermet
Global Communications Specialist
info@adacap.com
+33 (0)4 50 99 30 70

We inform you that the personal data you provide by sending this e-mail will be processed in compliance with ARTICLES 13 AND 14 OF REGULATION (EU) 2016/679 (GDPR) as referred to in the privacy policy on our website and which recalls the confidentiality obligations that inspire our company’s activity in order to be able to respond quickly and comprehensively to your request.

The processing of your personal data will be carried out using appropriate tools to ensure the security and confidentiality of the aforementioned data.

The methods of processing of data referred in this notice to here provide for applies for the use of manual, computerized and telematic tools.

Your data will be processed by employees and / or collaborators of AAA duly appointed for processing. Furthermore, AAA is part of a multinational Group, therefore it may be that your personal data are transferred to other countries, even outside the European Union, to parent companies, subsidiaries or affiliates, as well as to external service companies, even if only for technical-IT reasons. In these cases we will proceed to their transfer only in the presence of the provision of your consent.

The optional, explicit and voluntary sending of e-mail address or other data entered in the contact form to the official addresses indicated on this site entails the subsequent acquisition of the sender’s e-mail address necessary to respond to requests, as well as any other personal data entered. Specific summary information could be progressively reported or displayed on the pages of the website prepared for particular services on request.

The user confers the widest indemnity with respect to any objection, claim request for compensation for damage from treatment that should be received by the Data Controller from any third party concerned due to the provision of data indicated by the user in violation of the rules on protection of the personal data applicable according to the GDPR 2016/679.

THE REGULATION (EU) 2016/679 includes measures to protect and guarantee your rights, in particular, the interested party has the right at any time to obtain confirmation of the existence of personal data concerning him/her and to know its content and origin, verify its accuracy or request its integration or updating, or rectification. It also has the right to request the cancellation, transformation into anonymous form or blocking of data processed in violation of the law, as well as to oppose in any case, for legitimate reasons, to their processing. You may exercise these rights at any time by contacting us at: dpo@adacap.com.

To get more information about the website Privacy Policy, CLICK HERE.